Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.
Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.
复制标题
DOI：
10.1002/jso.24912
复制
发表时间：
2018-03
影响因子：
2.5
通讯作者：
Ajani JA
中科院分区：
文献类型：
--
作者：
Mizrak Kaya D;Nogueras-González GM;Harada K;Amlashi FG;Roy-Chowdhuri S;Estrella JS;Das P;Lee JH;Weston B;Bhutani MS;Matamoros A Jr;Thomas I;Lin Q;Badgwell BD;Ajani JA
腹膜细胞学检查阳性（+PCyt）或大体癌转移（GPC）预后不良。对于所有≥ T1 b胃腺癌（GAC），建议进行腹腔镜分期以检测+PCyt/GPC。对于具有基线−PCyt然后接受多模态治疗的GAC患者的自然史没有很好的记录，特别是对于随后GPC的风险。我们确定了238名基线为−PCyt的GAC患者，并对他们进行了腹膜癌病（PC）的随访。采用标准统计方法。在238例患者中，192例在术前治疗后尝试手术。其中，13例患者（6.8%）有GPC，1例有肝转移，因此手术中止。我们随访了164例接受R 0切除术的患者。中位随访时间为3.4（范围：0.6-18）年。PC发生率为13.4%（22/164例患者），至PC的中位时间为15.6个月。多因素分析显示，女性与PC相关。无后续PC患者的5年OS率为75%。即使在基线-Cyt水平下，约25%的患者在多模态治疗后发生PC。未发生PC的患者具有极好的OS率。进一步的研究是必要的，以检测PC在基线的生物标志物的使用。
Positive peritoneal cytology (+PCyt) or gross carcinomatosis (GPC) carries a poor prognosis. Laparoscopic staging to detect +PCyt/GPC is recommended for all ≥T1b gastric adenocarcinoma (GAC). The natural history of patients with GAC who have baseline −PCyt and then undergo multimodality therapy is not well documented, particularly for the risk of subsequent GPC. We identified 238 GAC patients with baseline −PCyt who were followed for the development of peritoneal carcinomatosis (PC). Standard statistical methods were employed. Of 238 patients, 192 had attempted surgery after preoperative therapy. Of these, 13 patients (6.8%) had GPC and 1 had liver metastases, thus surgery was aborted. We followed 164 patients who had an R0 resection. The median follow-up duration was 3.4 (range, 0.6–18) years. The rate of PC was 13.4%, (22/164 patients) and the median time to PC was 15.6 months. Female gender was associated with PC on multivariate analysis. The 5-year OS rate for patients without subsequent PC was 75%. Even with baseline −Cyt, ~25% of patients develop PC following multimodality therapy. Patients who do not develop PC have an excellent OS rate. Further research is warranted to detect PC at baseline by the use of biomarkers.
登录
查看更多内容
影响因子：
3.7
作者：
Ikoma, Naruhiko;Blum, Mariela;Badgwell, Brian D.
通讯作者：
Badgwell, Brian D.
影响因子：
9
作者：
Burke, EC;Karpeh, MS;Brennan, MF
通讯作者：
Brennan, MF
影响因子：
3.7
作者：
Takebayashi, Katsushi;Murata, Satoshi;Tani, Tohru
通讯作者：
Tani, Tohru
DOI：
10.1007/s10120-003-0257-0
发表时间：
2003-01-01
期刊：
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
影响因子：
--
作者：
Blackshaw, Guy R J C;Barry, Jonathan D;Lewis, Wyn G
通讯作者：
Lewis, Wyn G
影响因子：
254.7
作者：
Torre, Lindsey A.;Bray, Freddie;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin